Published Date: 06/05/2023
Expiration Date: 05/09/2026
The explosion of mpox that caught everybody by surprise and most severely affected our immunodeficient patients has receded, but is not gone. It is important now that mpox be included in our pantheon of sexually transmitted infections and include necessary preventive immunization for our patients at risk moving forward.
Preeti Pathela is the Executive Director of the STI Program in the Bureau of Hepatitis, HIV, and STI at the NYC DOHMH, with overall responsibility for directing, evaluating, and coordinating STI program implementation, surveillance and field operations, and epidemiology, research, and evaluation. She has 18 years of experience in STI/HIV prevention and control, serving previously as Director of STI Research and Evaluation at the NYC Health Department, where she oversaw a unit comprising analysts who examined data on STI/HIV patterns among the program’s sexual health clinic population, as well as at the citywide level, to generate and answer research questions around STD/HIV risk, prevention, and service delivery. She serves on the American STD Association’s Board of Directors and as an Associate Editor of Sexually Transmitted Diseases. Preeti received a Dr PH degree in Epidemiology from the Johns Hopkins Bloomberg School of Public Health and her MPH from Emory University.
